Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 08/02/2022

    New European Research Council grant for Max Plack Researcher

    The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-european-research-council-grant-max-plack-researcher
  • Press release - 03/02/2022

    The 5G-OR Project is a Winner of the joint Franco-German Program for the Development of innovative Applications for 5G private Networks

    5G-OR is one of the 4 winning projects jointly selected by the Federal Ministry of Economics and Climate Action in Germany and the Ministry of Economy, Finance and Relaunch in France for the call “Technical developments and application ecosystems for 5G private networks”. The joint Franco-German 5G-OR project takes up the challenge in the healthcare domain.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/5g-or-project-winner-joint-franco-german-program-development-innovative-applications-5g-private-networks
  • Press release - 20/12/2021

    Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome

    Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
  • Press release - 14/12/2021

    EU regulation approved: G-BA collaborates on European health technology assessment

    Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/eu-regulation-approved-g-ba-collaborates-european-health-technology-assessment
  • Press release - 29/11/2021

    Tracking down resistant cancer cells

    In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/tracking-down-resistant-cancer-cells
  • Funding

    Digital Europe Programme

    Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://biopro-v9-test-gi.xanium.io/en/database/funding/digital-europe-programme
  • Press release - 18/11/2021

    Overcoming resistance to treatment for breast, bowel, and pancreatic cancer

    As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
  • Press release - 18/11/2021

    Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system

    Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
  • Funding

    EU4Health- Programme

    Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://biopro-v9-test-gi.xanium.io/en/database/funding/eu4health-programme
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/innovative-drug-discovery
  • Press release - 13/08/2021

    Paradigm shift in immunology 'Adaptive Tolerance' balances autoimmune reaction

    Immunologists at Ulm University and its Medical Centre have developed a new model that could revolutionise the treatment of autoimmune disease as well as vaccine development. As 'Adaptive Tolerance' demonstrates, autoreactive antibodies are by no means disease drivers which a healthy organism swiftly eliminates. Rather, they trigger the formation of a class of antibodies that protect the body's own structures.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/paradigm-shift-immunology-adaptive-tolerance-balances-autoimmune-reaction
  • Press release - 26/07/2021

    Vaccination against hereditary colorectal cancer successful in mice

    Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/vaccination-against-hereditary-colorectal-cancer-successful-mice
  • Press release - 13/07/2021

    Breakthrough in research on age-related macular degenerationtion

    Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/breakthrough-research-age-related-macular-degenerationtion
  • Article - 08/07/2021 Schaubild, das in der Mitte den KoMed dargestellt durch aufeinandergestapelte Scheiben enthält. Von drei grau eingefärbten menschlichen Umrissen läuft ein Pfeil zum KoMed und von diesem zu blau eingefärbten Individuen. Die beteiligten Partner (UK HD, mint medical, PHILIPS, KARL STORZ, phellow seven) sind kreisförmig drumherum angeordnet.

    Individual operation risk assessment by the Cognitive Medical Assistant

    Despite modern surgical techniques and anaesthetic procedures, serious complications can occur during surgical interventions. An interdisciplinary team at Heidelberg University Hospital has launched a project called the Cognitive Medical Assistant (German: Der Kognitive Medizinische Assistant, KoMed for short), designed to better assess the individual risk of these interventions. The project’s goal is to systematically and comprehensively analyse…

    https://biopro-v9-test-gi.xanium.io/en/article/news/individual-operation-risk-assessment-cognitive-medical-assistant
  • Funding

    Horizone Europe

    Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://biopro-v9-test-gi.xanium.io/en/database/funding/horizone-europe
  • Press release - 10/06/2021

    Nose2Brain – Active substances without detour through the nose into the brain

    Effective drugs for the treatment of diseases of the central nervous system do exist. However, the blood-brain barrier, which protects the brain as the body's control center, makes it especially difficult for therapeutic biomolecules to pass through. Thus, researchers from an international consortium coordinated by the Fraunhofer IGB have spent the last four and a half years developing a novel system in the EU project "N2B-patch"…

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/nose2brain-active-substances-without-detour-through-nose-brain
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpeg

    Vaccines - a beacon of hope in the fight against pandemics

    https://biopro-v9-test-gi.xanium.io/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 21/04/2021

    Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding

    Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/atriva-therapeutics-kann-dank-foerdermitteln-covid-19-medikament-schneller-entwickeln
  • Press release - 13/04/2021

    Evotec’s BRIDGE “beLAB2122” leverages academic innovation from our region

    Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/evotecs-bridge-belab2122-leverages-academic-innovation-our-region
  • Quantum Technology Ulm - 08/04/2021 Quantro1.jpg

    Diamonds for life sciences innovations

    The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.

    https://biopro-v9-test-gi.xanium.io/en/article/news/diamonds-life-sciences-innovations
  • Press release - 03/03/2021

    New Baden-Württemberg network to reduce animal experiments

    A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/new-baden-wuerttemberg-network-reduce-animal-experiments
  • Press release - 28/01/2021

    Carl Zeiss Foundation funds Interdisciplinary practice Study at Heidelberg University with the sum of approximately of 4.5 Million Euros

    Can interconnected digital assistance systems enhance the quality of life of people in older age? Scientists in an interdisciplinary research project at Heidelberg University are exploring this question in a representative practice study. The participating researchers want to investigate how well these technical aids can be used and what benefit they achieve.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/carl-zeiss-foundation-funds-interdisciplinary-practice-study-heidelberg-university-sum-approximately-45-million-euros
  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https://biopro-v9-test-gi.xanium.io/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https://biopro-v9-test-gi.xanium.io/en/article/news/Ulms-simulator-has-europes-back
  • Innovations in the field of endoscopy - 08/06/2020 Computeranimation der Kamerapille im Dünndarm.

    Gastroscopies with pill cameras

    A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

    https://biopro-v9-test-gi.xanium.io/en/article/news/magenspiegelung-kamerapille

Page 4 / 6

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://biopro-v9-test-gi.xanium.io/en/search